Developer docs
API playgroundTry for free, no card

Search company profiles

Draupnir Bio

Full company profile

uuid0005ilq

Namestring
Draupnir Bio
Legal namestring
Draupnir Bio ApS
Websiteurl
draupnir.bio
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Draupnir Bio is a Danish preclinical biotechnology company developing oral small molecule protein degraders that target extracellular and membrane-bound disease-causing proteins—a category accounting for approximately 40% of the human proteome that first-generation PROTAC technologies cannot reach. The company's core technology is the proprietary SORTAC (Sortilin-based Lysosome Targeting Chimera) platform, a modular architecture consisting of a small molecule binding the sortilin lysosome receptor connected via a linker to a small molecule binding the extracellular disease protein. This ternary complex is internalized into the cell where the disease protein is destroyed while sortilin and the SORTAC are recycled, producing PROTAC-like catalytic activity and sustained target depletion. The platform offers multiple implementation formats including genetically encoded degraders, antibody conjugates, and fully synthetic small molecules, and its reliance on sortilin—which is expressed across all tissues—provides broad applicability across disease areas.

The pipeline is risk-diversified across three primary therapeutic areas: cardiovascular disease (originally PCSK9-targeted, the founding focus), inflammatory conditions (TNFα degradation in macrophages and Schwann cells, with successful proof-of-concept published in Cell Chemical Biology in March 2026), and neurodegenerative disease (alpha-synuclein degradation for Parkinson's disease via the DESYNA project, a three-year collaboration with Aarhus University funded by Innovation Fund Denmark with DKK 26.7M and targeted for preclinical validation by 2029). Key business inputs include the €30M Series A (October 2019), €12M seed round (July 2024), and additional non-dilutive grant funding, with a syndicate of European life sciences investors (Novo Holdings, Gilde Healthcare Partners, Inkef Capital) plus strategic investor MP Healthcare (Mitsubishi Tanabe Pharma's corporate venture) and EIFO.

Draupnir Bio generates no commercial revenue and operates under a licensing and partnership model. As a preclinical-stage company with 11-50 employees, it will monetize through pharmaceutical partnering, licensing deals, milestone payments, and potential royalties as candidates progress through clinical development and commercialization. Headquartered in Copenhagen with research operations at INCUBA Skejby in Aarhus, the company is led by CEO Andrew Hotchkiss (former Dermira/Immunocore/Eli Lilly executive) with co-founder Simon Glerup serving as CSO.

Short descriptiontext

Draupnir Bio is a Danish preclinical biotechnology company developing oral small molecule protein degraders targeting extracellular disease-causing proteins via its proprietary SORTAC platform, with pipeline programs in cardiovascular disease, inflammation, and Parkinson's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, extracellular protein degraders, small molecule therapeutics, lysosome receptor targeting, preclinical biotech platform
Industry1 code
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Targeted Protein Degradation Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Licensing
TypeLicensing Royalties
Description

As a preclinical biotech company, Draupnir Bio is developing a pipeline of oral small molecule protein degraders. Revenue will be generated through pharmaceutical partnerships, licensing deals, milestone payments, and potential commercialization of therapeutic products.

draupnir.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Draupnir Bio develops a preclinical pipeline of oral small molecule protein degraders using its proprietary SORTAC (Sortilin-based Lysosome Targeting Chimera) technology platform, which extends targeted protein degradation to extracellular and membrane-bound disease-causing proteins. The company targets validated and difficult-to-drug extracellular proteins for neurodegenerative diseases (Parkinson's via alpha-synuclein), inflammatory conditions (via TNFα degradation), and cardiovascular disease (via PCSK9). As a preclinical biotech, Draupnir plans to commercialize through pharmaceutical licensing deals, partnerships, and milestone payments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successful degradation of multiple therapeutically relevant targets including TNFα in macrophages and Schwann cells with hallmark PROTAC characteristics (ternary complex formation, catalytic activity, sustained target depletion)
Product overview1 text field

Draupnir Bio is a Danish biotechnology company that has developed the SORTAC (Sortilin-based Lysosome Targeting Chimera) technology platform as its core offering. The SORTAC platform enables targeted protein degradation of extracellular and membrane-bound disease-causing proteins, representing the next frontier of targeted protein degradation (TPD). The company is building a risk-diversified preclinical pipeline of oral small molecule protein degraders utilizing this platform, with programs targeting validated targets and traditionally difficult-to-drug proteins for potential treatment of inflammatory conditions, neurodegenerative diseases (Parkinson's), and cardiovascular disease.

Product and service3 records
1SORTAC Technology Platform
CategoryDrug Discovery Technology Platform
Description

Proprietary Sortilin-based Lysosome Targeting Chimera (SORTAC) technology platform that extends targeted protein degradation beyond cytosolic targets to extracellular and membrane-bound proteins (approximately 40% of the human proteome). The platform uses orally bioavailable small molecules that bind to sortilin via a linker to extracellular disease proteins, forming a ternary complex that redirects disease proteins to lysosomal degradation while sortilin and the SORTAC are recycled. Supports multiple implementation formats including genetically encoded degraders, antibody conjugates, and fully synthetic small molecules.

2DESYNA Parkinson's Disease Research Program
CategoryTherapeutic Pipeline Program
Description

Research program combining Draupnir Bio's SORTAC protein degradation technology with Aarhus University's neurodegeneration research to develop the world's first therapy targeting alpha-synuclein protein aggregates for Parkinson's disease. Funded by Innovation Fund Denmark with DKK 26.7 million investment.

3Extracellular Protein Degrader Pipeline (Inflammatory and Cardiovascular Programs)
CategoryTherapeutic Pipeline Program
Description

Risk-diversified preclinical pipeline of oral small molecule protein degraders targeting extracellular disease-causing proteins, including programs for inflammatory conditions via TNFα degradation and cardiovascular disease via PCSK9 targeting.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

DESYNA project collaboration combining Draupnir Bio's SORTAC protein degradation technology with Aarhus University's neurodegeneration research to develop therapies targeting alpha-synuclein aggregates for Parkinson's disease. The 3-year project aims to develop both injectable and oral treatment options with preclinical validation targeted for 2029.

2Max-Planck Society
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founding partner from which Draupnir Bio was spun out, based on breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.

draupnir.bio
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage pioneer in targeted protein degradation using PROTAC technology. Most direct peer in the TPD space with multiple clinical assets and major partnerships with Pfizer and Bayer, representing the established leader that Draupnir's SORTAC platform seeks to differentiate from.

TypeDirect peer
Description

Clinical-stage TPD company developing heterobifunctional degraders and molecular glues across immunology and oncology. Direct competitor in TPD modality with significant pharma partnerships (Sanofi, Vertex) and similar platform-based approach.

TypeDirect peer
Description

Clinical-stage TPD company with both degrader and E3 ligase modulator approaches. Direct competitor with multiple programs in immunology and oncology and a major partnership with Gilead.

TypeDirect peer
Description

Clinical-stage TPD company developing degraders using TORPEDO platform. Direct peer with similar small molecule degrader approach and partnerships with Biogen, Roche, and others.

TypeDirect peer
Description

European TPD company developing targeted protein degraders with a differentiated mechanism. Closely comparable as a European peer also working on novel TPD modalities with broader target reach than traditional PROTACs.

TypeDirect peer
Description

Clinical-stage biotechnology developing molecular glue degraders. Direct competitor in TPD space with similar focus on expanding the druggable proteome through induced protein degradation.

TypeEmerging player
Description

Clinical-stage company developing medicines targeting chromatin regulatory biology including through protein degradation. Partial overlap as another platform-based TPD approach with oncology focus.

TypeDirect peer
Description

European TPD company developing small molecule degraders for cancer and autoimmune diseases. Closely comparable as another European preclinical/early-clinical TPD platform company.

TypeEmerging player
Description

Preclinical/clinical TPD company developing bifunctional degraders. Comparable as a smaller TPD-focused biotech working on expanding protein degradation to broader target classes.

TypeEmerging player
Description

European biotech developing molecular glue degraders for historically undruggable targets. Comparable as European peer using novel E3 ligase approaches to enable protein degradation of difficult targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Draupnir Bio

Targeted Protein Degradation Therapeuticsdraupnir.bio

Draupnir Bio is a Danish preclinical biotechnology company developing oral small molecule protein degraders targeting extracellular disease-causing proteins via its proprietary SORTAC platform, with pipeline programs in cardiovascular disease, inflammation, and Parkinson's disease.

What Draupnir Bio does

Draupnir Bio is a Danish preclinical biotechnology company developing oral small molecule protein degraders that target extracellular and membrane-bound disease-causing proteins—a category accounting for approximately 40% of the human proteome that first-generation PROTAC technologies cannot reach. The company's core technology is the proprietary SORTAC (Sortilin-based Lysosome Targeting Chimera) platform, a modular architecture consisting of a small molecule binding the sortilin lysosome receptor connected via a linker to a small molecule binding the extracellular disease protein. This ternary complex is internalized into the cell where the disease protein is destroyed while sortilin and the SORTAC are recycled, producing PROTAC-like catalytic activity and sustained target depletion. The platform offers multiple implementation formats including genetically encoded degraders, antibody conjugates, and fully synthetic small molecules, and its reliance on sortilin—which is expressed across all tissues—provides broad applicability across disease areas.

The pipeline is risk-diversified across three primary therapeutic areas: cardiovascular disease (originally PCSK9-targeted, the founding focus), inflammatory conditions (TNFα degradation in macrophages and Schwann cells, with successful proof-of-concept published in Cell Chemical Biology in March 2026), and neurodegenerative disease (alpha-synuclein degradation for Parkinson's disease via the DESYNA project, a three-year collaboration with Aarhus University funded by Innovation Fund Denmark with DKK 26.7M and targeted for preclinical validation by 2029). Key business inputs include the €30M Series A (October 2019), €12M seed round (July 2024), and additional non-dilutive grant funding, with a syndicate of European life sciences investors (Novo Holdings, Gilde Healthcare Partners, Inkef Capital) plus strategic investor MP Healthcare (Mitsubishi Tanabe Pharma's corporate venture) and EIFO.

Draupnir Bio generates no commercial revenue and operates under a licensing and partnership model. As a preclinical-stage company with 11-50 employees, it will monetize through pharmaceutical partnering, licensing deals, milestone payments, and potential royalties as candidates progress through clinical development and commercialization. Headquartered in Copenhagen with research operations at INCUBA Skejby in Aarhus, the company is led by CEO Andrew Hotchkiss (former Dermira/Immunocore/Eli Lilly executive) with co-founder Simon Glerup serving as CSO.

Draupnir Bio firmographics

Firmographics
Name
Draupnir Bio
Legal name
Draupnir Bio ApS
Website
https://draupnir.bio
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Draupnir Bio is a Danish preclinical biotechnology company developing oral small molecule protein degraders targeting extracellular disease-causing proteins via its proprietary SORTAC platform, with pipeline programs in cardiovascular disease, inflammation, and Parkinson's disease.
Ownership category
akta.pro rank

Draupnir Bio industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Extracellular protein degraders
  • Small molecule therapeutics
  • Lysosome receptor targeting
  • Preclinical biotech platform

Where Draupnir Bio is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Draupnir Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Development and Licensing: As a preclinical biotech company, Draupnir Bio is developing a pipeline of oral small molecule protein degraders. Revenue will be generated through pharmaceutical partnerships, licensing deals, milestone payments, and potential commercialization of therapeutic products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Draupnir Bio product offering

Product offering

Core offering

Draupnir Bio develops a preclinical pipeline of oral small molecule protein degraders using its proprietary SORTAC (Sortilin-based Lysosome Targeting Chimera) technology platform, which extends targeted protein degradation to extracellular and membrane-bound disease-causing proteins. The company targets validated and difficult-to-drug extracellular proteins for neurodegenerative diseases (Parkinson's via alpha-synuclein), inflammatory conditions (via TNFα degradation), and cardiovascular disease (via PCSK9). As a preclinical biotech, Draupnir plans to commercialize through pharmaceutical licensing deals, partnerships, and milestone payments.

Product overview

Draupnir Bio is a Danish biotechnology company that has developed the SORTAC (Sortilin-based Lysosome Targeting Chimera) technology platform as its core offering. The SORTAC platform enables targeted protein degradation of extracellular and membrane-bound disease-causing proteins, representing the next frontier of targeted protein degradation (TPD). The company is building a risk-diversified preclinical pipeline of oral small molecule protein degraders utilizing this platform, with programs targeting validated targets and traditionally difficult-to-drug proteins for potential treatment of inflammatory conditions, neurodegenerative diseases (Parkinson's), and cardiovascular disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • SORTAC Technology Platform Proprietary Sortilin-based Lysosome Targeting Chimera (SORTAC) technology platform that extends targeted protein degradation beyond cytosolic targets to extracellular and membrane-bound proteins (approximately 40% of the human proteome). The platform uses orally bioavailable small molecules that bind to sortilin via a linker to extracellular disease proteins, forming a ternary complex that redirects disease proteins to lysosomal degradation while sortilin and the SORTAC are recycled. Supports multiple implementation formats including genetically encoded degraders, antibody conjugates, and fully synthetic small molecules.
  • DESYNA Parkinson's Disease Research Program Research program combining Draupnir Bio's SORTAC protein degradation technology with Aarhus University's neurodegeneration research to develop the world's first therapy targeting alpha-synuclein protein aggregates for Parkinson's disease. Funded by Innovation Fund Denmark with DKK 26.7 million investment.
  • Extracellular Protein Degrader Pipeline (Inflammatory and Cardiovascular Programs) Risk-diversified preclinical pipeline of oral small molecule protein degraders targeting extracellular disease-causing proteins, including programs for inflammatory conditions via TNFα degradation and cardiovascular disease via PCSK9 targeting.

Quantifiable outcome

  • Successful degradation of multiple therapeutically relevant targets including TNFα in macrophages and Schwann cells with hallmark PROTAC characteristics (ternary complex formation, catalytic activity, sustained target depletion)

Companies that use Draupnir Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Draupnir Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Draupnir Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Aarhus UniversitycoreStrategic or Co-development Partner · 23 March 2026DESYNA project collaboration combining Draupnir Bio's SORTAC protein degradation technology with Aarhus University's neurodegeneration research to develop therapies targeting alpha-synuclein aggregates for Parkinson's disease. The 3-year project aims to develop both injectable and oral treatment options with preclinical validation targeted for 2029.
  • Max-Planck SocietycoreStrategic or Co-development PartnerCo-founding partner from which Draupnir Bio was spun out, based on breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Draupnir Bio competitors and assessment

Company assessment

Direct peers

  • Arvinas: Clinical-stage pioneer in targeted protein degradation using PROTAC technology. Most direct peer in the TPD space with multiple clinical assets and major partnerships with Pfizer and Bayer, representing the established leader that Draupnir's SORTAC platform seeks to differentiate from.
  • Kymera Therapeutics: Clinical-stage TPD company developing heterobifunctional degraders and molecular glues across immunology and oncology. Direct competitor in TPD modality with significant pharma partnerships (Sanofi, Vertex) and similar platform-based approach.
  • Nurix Therapeutics: Clinical-stage TPD company with both degrader and E3 ligase modulator approaches. Direct competitor with multiple programs in immunology and oncology and a major partnership with Gilead.
  • C4 Therapeutics: Clinical-stage TPD company developing degraders using TORPEDO platform. Direct peer with similar small molecule degrader approach and partnerships with Biogen, Roche, and others.
  • Amphista Therapeutics: European TPD company developing targeted protein degraders with a differentiated mechanism. Closely comparable as a European peer also working on novel TPD modalities with broader target reach than traditional PROTACs.
  • Monte Rosa Therapeutics: Clinical-stage biotechnology developing molecular glue degraders. Direct competitor in TPD space with similar focus on expanding the druggable proteome through induced protein degradation.
  • Captor Therapeutics: European TPD company developing small molecule degraders for cancer and autoimmune diseases. Closely comparable as another European preclinical/early-clinical TPD platform company.

Emerging players

  • Foghorn Therapeutics: Clinical-stage company developing medicines targeting chromatin regulatory biology including through protein degradation. Partial overlap as another platform-based TPD approach with oncology focus.
  • BioTheryx: Preclinical/clinical TPD company developing bifunctional degraders. Comparable as a smaller TPD-focused biotech working on expanding protein degradation to broader target classes.
  • Proxygen: European biotech developing molecular glue degraders for historically undruggable targets. Comparable as European peer using novel E3 ligase approaches to enable protein degradation of difficult targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks4 records

Key highlights7 records

Customer concentration

Draupnir Bio social profiles

Digital presence

Draupnir Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Draupnir Bio leadership team

Management profile

Number of profiles

Profiles9 records

Draupnir Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Draupnir Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Draupnir Bio

What does Draupnir Bio do?

Draupnir Bio develops a preclinical pipeline of oral small molecule protein degraders using its proprietary SORTAC (Sortilin-based Lysosome Targeting Chimera) technology platform, which extends targeted protein degradation to extracellular and membrane-bound disease-causing proteins. The company targets validated and difficult-to-drug extracellular proteins for neurodegenerative diseases (Parkinson's via alpha-synuclein), inflammatory conditions (via TNFα degradation), and cardiovascular disease (via PCSK9). As a preclinical biotech, Draupnir plans to commercialize through pharmaceutical licensing deals, partnerships, and milestone payments.

Is Draupnir Bio a public or private company?

Draupnir Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Draupnir Bio founded?

Draupnir Bio was founded in 2017. It employs 11 to 50 people.

Where is Draupnir Bio based?

Draupnir Bio is headquartered in Copenhagen, Denmark, in the Europe region.

How does Draupnir Bio make money?

One revenue line is on record: pharmaceutical Development and Licensing.

Who are Draupnir Bio's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, Amphista Therapeutics, Monte Rosa Therapeutics and Captor Therapeutics. Emerging players are Foghorn Therapeutics, BioTheryx and Proxygen.

Does Draupnir Bio have an API?

No public API is recorded for Draupnir Bio.

What industry is Draupnir Bio in?

Draupnir Bio's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDraupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical BiologyDraupnir Bio published research in Cell Chemical Biology detailing its SORTAC platform for degrading extracellular proteins. The study shows in vitro and in vivo efficacy against targets like TNFα in macrophages and Schwann cells. The company says this validates its preclinical pipeline of oral small-molecule degraders.GlobeNewswireDraupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical BiologyDraupnir Bio, a Danish biotechnology company, announced the publication of research in Cell Chemical Biology detailing its proprietary SORTAC (sortilin-based lysosome targeting chimera) technology, which extends targeted protein degradation beyond cytosolic proteins to the extracellular space, targeting the previously inaccessible 40% of the human proteome. The study demonstrated the platform's efficacy through successful degradation of multiple therapeutically relevant targets, including the inflammatory cytokine TNFα in macrophages and Schwann cells, with hallmark PROTAC characteristics including ternary complex formation, catalytic activity, and sustained target depletion. The publication validates the scientific foundation for Draupnir's preclinical pipeline of oral small molecule degraders targeting extracellular disease-causing proteins.BioSpaceDraupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical BiologyDraupnir Bio announced the publication of research in Cell Chemical Biology detailing its SORTAC (sortilin-based lysosome targeting chimera) technology platform, which extends targeted protein degradation beyond cytosolic targets to extracellular and membrane-bound proteins, representing approximately 40% of the human proteome. The study demonstrated the platform's versatility through successful degradation of therapeutically relevant targets, including the inflammatory cytokine TNFα in macrophages and Schwann cells, showing hallmark PROTAC characteristics including ternary complex formation, catalytic activity, and sustained target depletion. The publication validates Draupnir's scientific approach and strengthens the foundation for its risk-diversified preclinical pipeline of oral small molecule degraders of extracellular targets.GlobeNewswireGroundbreaking Danish research project launches to cure Parkinson’s diseaseInnovation Fund Denmark has invested DKK 26.7 million in the DESYNA research project, a collaboration between Danish biotech company Draupnir Bio and Aarhus University to develop a therapy targeting alpha-synuclein aggregates in Parkinson's disease. The therapy aims to completely degrade toxic protein aggregates and prevent their cell-to-cell spread, potentially becoming the first treatment to change the disease's course rather than just managing symptoms. The three-year project combines Draupnir Bio's SORTAC protein degradation technology with Aarhus University's neurodegeneration research, targeting preclinical validation candidates by 2029 with both injectable and oral formulations.BioSpaceGroundbreaking Danish research project launches to cure Parkinson’s diseaseA Danish research project called DESYNA has launched with DKK 26.7 million in funding from Innovation Fund Denmark to develop what it claims would be the world's first therapy targeting alpha-synuclein protein aggregates to potentially cure Parkinson's disease. The three-year project combines protein degradation technology from Danish biotech company Draupnir Bio with neurodegeneration research from Aarhus University, aiming to halt disease progression rather than just manage symptoms. The collaboration seeks to develop both injectable and oral treatment options, with the goal of reaching preclinical validation by 2029.Startup DopeDraupnir Bio Secures €12 Million Seed Funding to Pioneer Extracellular Protein Degradation – Startup DopeDanish biotechnology company Draupnir Bio has secured €12 million in seed funding led by MP Healthcare and EIFO to develop oral, small-molecule degraders for extracellular proteins. The capital will be used to advance its preclinical pipeline of Targeted Protein Degradation (TPD) therapies that target disease-causing proteins located outside cells. This approach aims to expand treatable conditions beyond the intracellular limitations of current TPD technologies.FinSMEsDraupnir Bio Completes €12M Seed FundingDraupnir Bio, a biotechnology company based in Copenhagen, Denmark, has completed €12 million in seed funding. The investment was led by backers including MP Healthcare and EIFO, alongside existing investors Gilde Healthcare Partners, Inkef Capital, and Novo Holdings. Draupnir Bio intends to utilize these funds to advance its preclinical pipeline of oral, small molecule protein degraders.GlobeNewswireDraupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteinsDraupnir Bio raised €12 million in seed funding from MP Healthcare, EIFO, and existing investors to develop oral small molecule degraders of extracellular proteins. The company's technology targets 40% of the human proteome, including membrane-bound proteins. Proceeds will advance its preclinical pipeline.The European Life Sciences Web PortalDraupnir Bio–Denmark (govt): Investment, 202407 seed financing round totalling €12m incl new investor EIFODraupnir Bio completed a €12 million seed financing round to advance the development of its oral small molecule degraders for extracellular proteins. New investors MP Healthcare and EIFO joined existing backers Gilde Healthcare Partners, Inkef Capital, and Novo Holdings in the investment. The funds will support the company's preclinical pipeline targeting previously undruggable disease-causing proteins.DraupnirDraupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteinsDraupnir Bio has secured a €12 million seed round from investors MP Healthcare and EIFO to advance its development of oral small molecule degraders targeting extracellular proteins. The funding supports the company's proprietary technology platform, which aims to expand targeted protein degradation beyond cytosolic targets to address historically undruggable disease-causing proteins.